113,568 Shares in AbbVie Inc. $ABBV Purchased by Daiichi Life Insurance Co. Ltd.

Daiichi Life Insurance Co. Ltd. purchased a new stake in AbbVie Inc. (NYSE:ABBV) in the second quarter, Holdings Channel.com reports. The firm purchased 113,568 shares of the company’s stock, valued at approximately $28,578,000.

Other hedge funds have also recently bought and sold shares of the company. Norges Bank purchased a new position in shares of AbbVie during the 4th quarter valued at approximately $5,865,055,000. Wellington Management Group LLP grew its position in shares of AbbVie by 457.4% during the third quarter. Wellington Management Group LLP now owns 10,536,901 shares of the company’s stock worth $2,439,714,000 after buying an additional 8,646,424 shares in the last quarter. Capital World Investors increased its stake in shares of AbbVie by 106.3% in the fourth quarter. Capital World Investors now owns 13,071,444 shares of the company’s stock worth $2,986,777,000 after buying an additional 6,736,161 shares during the last quarter. Cardano Risk Management B.V. raised its holdings in AbbVie by 914.6% in the fourth quarter. Cardano Risk Management B.V. now owns 5,444,930 shares of the company’s stock valued at $1,244,112,000 after acquiring an additional 4,908,260 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in AbbVie by 10.4% in the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock valued at $10,179,099,000 after acquiring an additional 4,190,487 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

Insider Buying and Selling at AbbVie

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction dated Friday, August 14th. The shares were sold at an average price of $250.00, for a total value of $8,177,500.00. Following the sale, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This trade represents a 30.53% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.06% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

ABBV has been the topic of a number of research analyst reports. Canaccord Genuity Group increased their price objective on shares of AbbVie from $282.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 3rd. Guggenheim increased their price target on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a research report on Tuesday, August 4th. Wolfe Research upgraded AbbVie from a “peer perform” rating to an “outperform” rating and set a $300.00 price target for the company in a research note on Thursday, August 13th. UBS Group boosted their price objective on AbbVie from $230.00 to $260.00 and gave the company a “neutral” rating in a report on Monday, July 13th. Finally, Royal Bank Of Canada upped their price objective on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research note on Friday, July 10th. Two analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $275.95.

AbbVie Price Performance

NYSE:ABBV opened at $261.50 on Thursday. AbbVie Inc. has a 12-month low of $190.75 and a 12-month high of $267.47. The firm has a market capitalization of $462.02 billion, a P/E ratio of 73.87, a P/E/G ratio of 1.18 and a beta of 0.29. The business has a 50 day simple moving average of $254.23 and a 200 day simple moving average of $229.67.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, July 31st. The company reported $3.65 EPS for the quarter, topping analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a negative return on equity of 422.07% and a net margin of 9.80%.The firm had revenue of $16.99 billion during the quarter, compared to the consensus estimate of $16.80 billion. During the same period in the prior year, the business earned $2.97 EPS. The firm’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. Research analysts anticipate that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, August 14th. Stockholders of record on Wednesday, July 15th were given a dividend of $1.73 per share. The ex-dividend date was Wednesday, July 15th. This represents a $6.92 annualized dividend and a dividend yield of 2.6%. AbbVie’s dividend payout ratio is currently 195.48%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.